MOVE: using multi-omics to design better HIV vaccines
The Multi-omics Vaccine Evaluation (MOVE) Consortium
Researchers are developing an HIV vaccine approach that uses detailed biological data (multi-omics) to teach the immune system to make powerful antibodies that can block many HIV strains.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11312601 on NIH RePORTER |
What this research studies
You would be hearing about a team that combines lots of different biological measurements (genes, proteins, immune cell behavior and more) to guide vaccine design at each step. Instead of one vaccine ingredient, they are building combinations and sequences of immunogens to try to train the body to make several types of broadly neutralizing antibodies at once. The work uses advanced lab methods, animal models, and human-derived samples to speed up which vaccine ideas move forward. The goal is a faster, more reliable path from lab findings to vaccine candidates that could enter clinical testing.
Who could benefit from this research
Good fit: People at risk for HIV infection or volunteers who join future vaccine trials would be the most likely candidates to participate.
Not a fit: People already living with established HIV infection are unlikely to receive direct benefit from a preventive vaccine program.
Why it matters
Potential benefit: If successful, this approach could produce an HIV vaccine that prevents infection by guiding the immune system to make antibodies that neutralize diverse HIV strains.
How similar studies have performed: Previous vaccine efforts have had limited success inducing broadly neutralizing antibodies in humans, so integrating multi-omics across vaccine design is a relatively novel and ambitious strategy.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Briney, Bryan — Scripps Research Institute, the
- Study coordinator: Briney, Bryan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.